What is Retatrutide and how does it work?

Retatrutide is an investigational medication that acts on three key metabolic receptors: GLP-1, GIP, and glucagon. This multi-target approach helps reduce appetite, slow digestion, increase energy expenditure, and improve insulin sensitivity, leading to significant weight loss and better blood sugar control.

How should I prepare for my Retatrutide treatment?

Preparation involves an initial medical consultation to ensure eligibility, comprehensive blood tests, and a discussion about potential side effects and proper administration. You will typically start with a low dose, gradually increasing as advised by your healthcare provider to help your body adjust.

What kind of results can I expect and how long does treatment last?

Clinical trials have shown patients experiencing average weight reductions of up to 24-29% of their body weight. Treatment duration is personalized, but it is a longer-term therapy requiring consistent adherence. Benefits extend beyond weight loss to improving glycemic control, liver health, and reducing knee osteoarthritis pain.

Retatrutide

Pioneering Retatrutide therapy offers significant weight loss and comprehensive metabolic health improvements for obesity and Type 2 Diabetes.

5 minwith specialist Mohamed Wagih Abdelsalam Eldeeb

Book appointment

Quick answer

Pioneering Retatrutide therapy offers significant weight loss and comprehensive metabolic health improvements for obesity and Type 2 Diabetes.

Options

Pick what fits

Standard

5 min

Benefits

What to expect

Significant Body Weight Reduction
Improved Glycemic Control (HbA1c Reduction)
Reduction in Liver Steatosis
Relief of Knee Osteoarthritis Pain in Obese Patients

Ideal for

Who this helps

Adults with Obesity (BMI >30 kg/m²)Adults with Type 2 Diabetes Mellitus seeking improved glycemic control and weight managementIndividuals with metabolic syndrome components seeking comprehensive metabolic improvement

How it works

The procedure

Retatrutide acts as a triple receptor agonist, activating GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors.

Activation of GLP-1 and GIP receptors enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite.

Glucagon receptor agonism may increase energy expenditure and fat metabolism, contributing to significant weight loss.

The combined effect leads to profound reductions in body weight, improved glycemic control, and beneficial metabolic adaptations across multiple organ systems.

Conditions